These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19372566)

  • 1. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model.
    VanderPorten EC; Taverna P; Hogan JN; Ballinger MD; Flanagan WM; Fucini RV
    Mol Cancer Ther; 2009 Apr; 8(4):930-9. PubMed ID: 19372566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
    Arbitrario JP; Belmont BJ; Evanchik MJ; Flanagan WM; Fucini RV; Hansen SK; Harris SO; Hashash A; Hoch U; Hogan JN; Howlett AR; Jacobs JW; Lam JW; Ritchie SC; Romanowski MJ; Silverman JA; Stockett DE; Teague JN; Zimmerman KM; Taverna P
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):707-17. PubMed ID: 19649632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
    Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
    Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
    Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
    Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells.
    Kaestner P; Stolz A; Bastians H
    Mol Cancer Ther; 2009 Jul; 8(7):2046-56. PubMed ID: 19584233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
    Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
    Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
    Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
    Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a potent and selective aurora kinase inhibitor.
    Oslob JD; Romanowski MJ; Allen DA; Baskaran S; Bui M; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris S; Heumann SA; Hoch U; Jacobs JW; Lam J; Lawrence CE; McDowell RS; Nannini MA; Shen W; Silverman JA; Sopko MM; Tangonan BT; Teague J; Yoburn JC; Yu CH; Zhong M; Zimmerman KM; O'Brien T; Lew W
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4880-4. PubMed ID: 18678489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents.
    Dowling M; Voong KR; Kim M; Keutmann MK; Harris E; Kao GD
    Cancer Biol Ther; 2005 Feb; 4(2):197-206. PubMed ID: 15753652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
    Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
    Zhou N; Singh K; Mir MC; Parker Y; Lindner D; Dreicer R; Ecsedy JA; Zhang Z; Teh BT; Almasan A; Hansel DE
    Clin Cancer Res; 2013 Apr; 19(7):1717-28. PubMed ID: 23403633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity.
    LeRoy PJ; Hunter JJ; Hoar KM; Burke KE; Shinde V; Ruan J; Bowman D; Galvin K; Ecsedy JA
    Cancer Res; 2007 Jun; 67(11):5362-70. PubMed ID: 17545617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.
    Cheung CH; Lin WH; Hsu JT; Hour TC; Yeh TK; Ko S; Lien TW; Coumar MS; Liu JF; Lai WY; Shiao HY; Lee TR; Hsieh HP; Chang JY
    PLoS One; 2011; 6(8):e23485. PubMed ID: 21887256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.
    Shan W; Akinfenwa PY; Savannah KB; Kolomeyevskaya N; Laucirica R; Thomas DG; Odunsi K; Creighton CJ; Lev DC; Anderson ML
    Clin Cancer Res; 2012 Jun; 18(12):3352-65. PubMed ID: 22535157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents.
    Wysong DR; Chakravarty A; Hoar K; Ecsedy JA
    Cell Cycle; 2009 Mar; 8(6):876-88. PubMed ID: 19221504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high throughput, whole cell screen for small molecule inhibitors of the mitotic spindle checkpoint identifies OM137, a novel Aurora kinase inhibitor.
    DeMoe JH; Santaguida S; Daum JR; Musacchio A; Gorbsky GJ
    Cancer Res; 2009 Feb; 69(4):1509-16. PubMed ID: 19190331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
    Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
    Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacodynamic model of Aurora kinase inhibitors in the spindle assembly checkpoint.
    Mistry HB; MacCallum DE; Jackson RC; Chaplain MA; Davidson FA
    Front Biosci (Landmark Ed); 2010 Jan; 15(1):249-58. PubMed ID: 20036819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors.
    Skobeleva N; Menon S; Weber L; Golemis EA; Khazak V
    Mol Cancer Ther; 2007 Mar; 6(3):898-906. PubMed ID: 17363484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
    Azzariti A; Bocci G; Porcelli L; Fioravanti A; Sini P; Simone GM; Quatrale AE; Chiarappa P; Mangia A; Sebastian S; Del Bufalo D; Del Tacca M; Paradiso A
    Br J Cancer; 2011 Mar; 104(5):769-80. PubMed ID: 21304529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.